Insulin resistance and obesity in a mouse model of systemic lupus erythematosus
- PMID: 16982954
- DOI: 10.1161/01.HYP.0000243612.02929.df
Insulin resistance and obesity in a mouse model of systemic lupus erythematosus
Abstract
Accumulating data indicate that metabolic syndrome is an inflammatory condition. Systemic lupus erythematosus (SLE) is an autoimmune disorder associated with nephritis and cardiovascular disease. Evidence suggests that individuals with SLE are at risk for developing insulin resistance; however, this has not been directly examined. Using an established mouse strain with SLE (NZBWF1), we examined whether SLE is associated with increased body weight and fat deposition. Mean arterial pressure was significantly increased (140+/-4 versus 114+/-2 mm Hg; n > or = 5) in SLE mice by 36 weeks of age compared with control mice (NZW/LacJ). Body weight in SLE mice was higher at each age compared with controls by 12%, 22%, and 34% (n > 30). Visceral adipose tissue weight was increased in SLE by 44%, 74%, and 117% at 8, 20, and 36 weeks, respectively (n > or = 12). Plasma leptin was increased in SLE mice (8.6+/-1.0 versus 24.7+/-2.2 ng/mL; n = 5), and renal and adipose tissue exhibited macrophage infiltration. Fasted insulin was higher in SLE mice (0.6+/-0.1 versus 1.4+/-0.3 ng/mL; n > or = 10), but fasted glucose was not different (94+/-5 versus 80+/-9; n > or = 9). A glucose tolerance test caused a significantly greater and longer increase in blood glucose from mice with SLE compared with control mice. Food intake was not different between control and SLE mice. However, mice with SLE demonstrated lower levels of nighttime activity than controls. These data show that the NZBWF1 strain may be an important model to study the effects of obesity and insulin resistance on SLE-associated hypertension.
Comment in
-
Insulin resistance and obesity in a mouse model of systemic lupus erythematosus.Hypertension. 2007 Feb;49(2):e12; author reply e13. doi: 10.1161/01.HYP.0000254320.49148.1d. Epub 2006 Dec 11. Hypertension. 2007. PMID: 17159078 No abstract available.
Similar articles
-
Endothelin receptor antagonism improves glucose tolerance and adipose tissue inflammation in an experimental model of systemic lupus erythematosus.Am J Physiol Endocrinol Metab. 2023 Jan 1;324(1):E73-E84. doi: 10.1152/ajpendo.00274.2022. Epub 2022 Dec 7. Am J Physiol Endocrinol Metab. 2023. PMID: 36476039 Free PMC article.
-
Insulin resistance and obesity in a mouse model of systemic lupus erythematosus.Hypertension. 2007 Feb;49(2):e12; author reply e13. doi: 10.1161/01.HYP.0000254320.49148.1d. Epub 2006 Dec 11. Hypertension. 2007. PMID: 17159078 No abstract available.
-
Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus.Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1286-92. doi: 10.1152/ajpregu.00079.2011. Epub 2011 Sep 7. Am J Physiol Regul Integr Comp Physiol. 2011. PMID: 21900645 Free PMC article.
-
Prolactin and systemic lupus erythematosus.Ann Med Interne (Paris). 1996;147(4):253-8. Ann Med Interne (Paris). 1996. PMID: 8952744 Review.
-
Genetic basis of murine lupus.Autoimmun Rev. 2004 Jan;3(1):33-9. doi: 10.1016/S1568-9972(03)00062-4. Autoimmun Rev. 2004. PMID: 14871647 Review.
Cited by
-
Leptin antagonism attenuates hypertension and renal injury in an experimental model of autoimmune disease.Clin Sci (Lond). 2023 Dec 14;137(23):1771-1785. doi: 10.1042/CS20230924. Clin Sci (Lond). 2023. PMID: 38031726 Free PMC article.
-
Endothelin receptor antagonism improves glucose tolerance and adipose tissue inflammation in an experimental model of systemic lupus erythematosus.Am J Physiol Endocrinol Metab. 2023 Jan 1;324(1):E73-E84. doi: 10.1152/ajpendo.00274.2022. Epub 2022 Dec 7. Am J Physiol Endocrinol Metab. 2023. PMID: 36476039 Free PMC article.
-
Development of High Fat Diet-Induced Hyperinsulinemia in Mice Is Enhanced by Co-treatment With a TLR7 Agonist.Front Physiol. 2022 Jul 6;13:930353. doi: 10.3389/fphys.2022.930353. eCollection 2022. Front Physiol. 2022. PMID: 35874527 Free PMC article.
-
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021.Int J Mol Sci. 2022 Jan 12;23(2):786. doi: 10.3390/ijms23020786. Int J Mol Sci. 2022. PMID: 35054972 Free PMC article. Review.
-
Autoimmune-mediated renal disease and hypertension.Clin Sci (Lond). 2021 Sep 17;135(17):2165-2196. doi: 10.1042/CS20200955. Clin Sci (Lond). 2021. PMID: 34533582 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
